Today: 8 February 2026
Subscribe

Rolex Price “Crash”? Experts Say It’s Just a Healthy Correction

Rolex Price “Crash”? Experts Say It’s Just a Healthy Correction

Post-Boom Reality Check: Why Prices Are Falling During the COVID lockdown and recovery (2020–22), Rolex prices on the secondary market soared to unprecedented highs. Super-rare models were trading at multiples of retail (for example, the Tiffany Blue Oyster Perpetual jumped from ~$5K retail to £30K usedinkl.com). This “mania” phase saw average Rolex values nearly double in just two yearsquillandpad.com. However, that bubble has now burst. By late 2023 and into 2024, dealers saw more and more unsold inventory and declining bids. As the IBTimes report explains, as soon as sellers started undercutting each other, prices for common models (like the Submariner or GMT‑Master II) fell
11 October 2025
Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Overview of Strive and Its Role: Strive Asset Management began as an ETF issuer and anti-ESG investment firm (co-founded by Ramaswamy in 2022)etf.comglobenewswire.com. In 2025 it transformed into a dedicated Bitcoin-treasury company. Strive’s business is to raise capital (through equity/debt) and convert it into Bitcoin holdings. The company uses a “preferred equity only” leverage model (no debt) to accumulate cryptoglobenewswire.com. By merger and acquisitions, Strive aims to become a large public company that simply hoards Bitcoin. Its own COO calls this building a “scaled, innovative and accretive Bitcoin acquisition platform”globenewswire.com. In practice, Strive is effectively a corporatized Bitcoin ETF: shareholders
11 October 2025
··
Visa (V) Stock Poised for a Surge? Crypto Pilot and Travel Deals Fuel Optimism

Visa (V) Stock Poised for a Surge? Crypto Pilot and Travel Deals Fuel Optimism

Stock Price and Recent Performance Visa trades under the ticker V on the NYSE. After markets closed on Friday, Oct 10, 2025, Visa was about $343.65investor.visa.com per share, down ~$3 (roughly 1%) on the day. (Its intraday range was roughly $343–$350.) Earlier in the week, the stock dipped to a new 2025 low when the DOJ antitrust news brokeainvest.com. Year-to-date (Jan–Oct 2025), Visa’s stock is up on the order of 10–12%. For context, Reuters reported that by late July Visa was up ~13% for the year, versus +8% for Mastercard and –10% for AmExreuters.com. By late July, Visa’s price gains
11 October 2025
·
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

Stock Performance & Recent Trends AbbVie’s stock closed at $230.88 on Oct. 10, 2025marketbeat.com. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50investing.com. Notably, on Sept. 30 ABBV hit a 52-week high around $244.8, buoyed by regulatory filings and a sector-wide rally. From that late-September peak it has pulled back into the low-$230s as investors digest upcoming FDA news. On Oct. 1 the entire pharma sector rallied (+5% in Europe) after Pfizer announced a U.S. drug-pricing dealreuters.com; AbbVie’s shares jumped ~6–8% that day as well. Technicals (50-day MA ≈ $214; 200-day MA ≈ $197) remain
11 October 2025
··
AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

Company Background AstraZeneca PLC is a leading Anglo-Swedish pharmaceutical giant specializing in oncology, respiratory, cardiovascular/metabolic, and rare disease medicinesmarketbeat.comastrazeneca.com. Headquartered in Cambridge, UK, it maintains primary listings on the London Stock Exchange and Nasdaq Stockholm, with secondary ADR trading in the U.S.astrazeneca.com. The company was formed in 1999 by merging Sweden’s Astra AB and the UK’s Zeneca. Its 2024 revenues were $54.07 billionastrazeneca.com, driven by top-selling drugs like Tagrisso (lung cancer), Lynparza (ovarian cancer), Farxiga (diabetes), and Symbicort (asthma)marketbeat.com. In its 2024 Annual Report, AZN describes itself as “a global, science-led, patient-focused pharmaceutical business” and targets $80B in sales by 2030
11 October 2025
·
Pinterest Stock Takes on Gen Z: Is PINS the Next AI-Powered Shopping Juggernaut?

Pinterest Stock Takes on Gen Z: Is PINS the Next AI-Powered Shopping Juggernaut?

Overview – Company & Business Model Pinterest, Inc. (NYSE:PINS) is a visual search and discovery platform launched in 2010investor.pinterestinc.com. Users (“pinners”) browse and save image-based “Pins” on topics from fashion and home decor to recipes and travel, often linking to products or content. The site’s tagline – “where people discover new ideas, plan and shop” – reflects its e-commerce focus. Pinterest has over half a billion MAUs globally (578M in Q2’25)investor.pinterestinc.com; two-thirds of users are women, and more than 50% now are Gen Zinvestor.pinterestinc.com. Crucially, Pinterest is free to users and monetizes almost exclusively through ads. Advertisers buy Promoted Pins, search
11 October 2025
···
CNQ Stock Skyrocketing? Oil Rally, 25-Year Dividends & Expert Forecasts (Oct 2025)

CNQ Stock Skyrocketing? Oil Rally, 25-Year Dividends & Expert Forecasts (Oct 2025)

CNQ Stock Price & Recent Performance CNQ’s stock has climbed in recent weeks. The TSX-listed share reached ~C$45.55 on Oct 9simplywall.st (about $31.40 on NYSE). This is near its 3-year high (∼C$48), though still below the 2023 peak (~C$52). Over the last week it gained ~3%simplywall.st, driven by a bounce in oil prices and positive sentiment. For context, CNQ is up ~45% over 3 years and nearly +400% over 5 yearssimplywall.st, illustrating its strong long-term return. In intraday action on Oct 10, CNQ did fall (~4%) on heavy volume, partly reflecting a broad market selloffoilprice.comand some specific worries (see below). However,
11 October 2025
··
Is Duke Energy (DUK) Poised to Soar? Top 5 Things Investors Need to Know

Is Duke Energy (DUK) Poised to Soar? Top 5 Things Investors Need to Know

Stock Price and Recent Performance As of the Oct 10 close, Duke Energy trades around $127. It has rallied from the mid-$110s over the past few months and hit a 2025 high after the Oct 10 sessionainvest.com. Trading volume has been moderate. Over the last week it is up a few percent, building on solid gains in early October. In the past five years DUK returned ~+62%simplywall.st, handily outperforming the S&P 500 Utilities sector. Duke’s stability and dividend yield have made it attractive: investors “have been leaning into reliable utility stocks amid broader uncertainty,” boosting Duke’s share price as noted by Simply Wall Stsimplywall.st. Looking
11 October 2025
3M Stock Set to Soar! PFAS Settlement and Dividends Spark Rally (Oct 2025)

3M Stock Set to Soar! PFAS Settlement and Dividends Spark Rally (Oct 2025)

Stock Price & Recent Performance 3M’s stock has been trading in the low-to-mid $150s this autumn. As of Oct 10, 2025, it closed near $148.75tradingview.com. That day’s drop (~–2.7%) came amid broad market pullback. Over the past week MMM has slid roughly –6.4%tradingview.com, reversing part of its earlier gains. (Year-to-date MMM was up ~10.6%tradingview.com, roughly in line with the S&P 500.) The 52-week trading range is about $122–$164, with 50-day and 200-day moving averages near $154 and $149 respectivelymarketbeat.com. Technical indicators show MMM recently lost some momentum. Chart analysis highlights a support zone around $146–147 and resistance near $156–167. For example, AI-driven signals mark current support
11 October 2025
·
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Metric Merck (MRK) Last Price (10/10/25) $86.02marketbeat.com Market Cap $215Bmarketbeat.com P/E (TTM) ~13×marketbeat.com Yield 3.8%marketbeat.com 52-Week Range $73.31 – $111.58marketbeat.com YTD Total Return -11.07%financecharts.com Q2 2025 Sales $15.8Binvesting.com 2024 Sales $64.2Bmerck.com 2024 R&D Spend $17.9Bmerck.com Analyst PT (avg) $104 (12-mo)marketbeat.com Consensus Rating Holdmarketbeat.com Company Overview Merck & Co. (MRK, called MSD outside North America) is a global healthcare company (75,000 employeesmerck.com) organized in Pharmaceuticals, Vaccines and Animal Health. It focuses on oncology/immunology, infectious disease (including vaccines), cardio-metabolic, and hospital specialty medicinesmerck.com. Its blockbuster product KEYTRUDA® (pembrolizumab) – a PD-1 checkpoint inhibitor – has driven Merck’s growth, accounting for >50% of pharma sales in
11 October 2025
·
Coca-Cola (KO) Stock: 7 Surprising Facts You Need to Know (Oct 11, 2025)

Coca-Cola (KO) Stock: 7 Surprising Facts You Need to Know (Oct 11, 2025)

Figure: A Coca-Cola distribution truck in downtown Los Angeles (2018). The company’s products are delivered globally. Coke sells roughly 2 billion servings per day (over 700 million ounces) worldwide. It is a Dow-30 component and one of the largest non-alcoholic beverage companies. In emerging markets, KO often drives growth (e.g. Coca-Cola and local brands like Thums Up achieved double-digit volume growth in Indiainvestors.coca-colacompany.com). Figure: Coca-Cola products (Coke, Sprite, etc.) on the shelf of a Sarajevo supermarket (Bosnia, 2024). The brand’s retail presence spans countless stores globally. Sources: Authoritative analyses and news (Reuters, MarketBeat, SimplyWallSt, TS2.Tech, Motley Fool, etc.) have been used throughout this report to
11 October 2025
Circle (CRCL) Stock’s Wild Ride: Stablecoin Boom, Volatile Swings & 2025 Outlook

Circle (CRCL) Stock’s Wild Ride: Stablecoin Boom, Volatile Swings & 2025 Outlook

Recent Developments & News (October 2025) October 2025 has been eventful for Circle, with major partnership news and stock volatility grabbing headlines. On Sept 30, Circle revealed a collaboration with Deutsche Börse, one of the world’s largest market infrastructure providers, to integrate its stablecoins into traditional capital markets ts2.tech. This deal will explore listing USDC/EURC on Deutsche Börse’s trading platforms and using Circle’s coins in settlement and custody via the exchange’s networks ts2.tech. Around the same time, Circle announced fintech firms Arf and Huma joined its Circle Payments Network to offer credit and liquidity services in USDC ts2.tech – part
11 October 2025
···
Uranium Energy Corp (UEC) Stock Skyrockets on Nuclear Boom – Key Facts & Outlook

Uranium Energy Corp (UEC) Stock Skyrockets on Nuclear Boom – Key Facts & Outlook

Overview of Uranium Energy Corp (UEC) Uranium Energy Corp is a U.S.-based uranium mining and exploration company founded in 2003 (NYSE American: UEC). Headquartered in Corpus Christi, Texas, UEC has become “America’s largest and fastest growing supplier of uranium” for nuclear energy prnewswire.com. The company’s business model focuses on low-cost in-situ recovery (ISR) mining in the United States and high-grade conventional uranium projects in Canada prnewswire.com. This two-pronged approach lets UEC rapidly develop domestic uranium sources while also holding stakes in some of the world’s richest uranium districts. UEC operates on a “hub-and-spoke” strategy for ISR production. It has three
11 October 2025
NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

Company Overview: History & Mission NewAmsterdam Pharma Company N.V. is a Netherlands-based biotech (with U.S. operations in Miami) on a mission to “change the landscape of lipid-lowering treatment” for cardiovascular disease Newamsterdampharma. Founded in early 2020, the company sprang from the vision of Prof. John J.P. Kastelein – a world-renowned expert in lipid disorders – and venture capital firm Forbion Newamsterdampharma. They acquired the rights to obicetrapib, a once-abandoned CETP inhibitor, from an Amgen subsidiary in 2020 Newamsterdampharma. Soon after, Dr. Michael Davidson (a leading preventive cardiologist) joined as co-founder and CEO, bringing deep clinical expertise to the leadership team
11 October 2025
Broadcom’s AI Windfall: Inside AVGO’s Trillion-Dollar Surge, $10B Chip Deal & 2025 Outlook

Broadcom’s AI Windfall: Inside AVGO’s Trillion-Dollar Surge, $10B Chip Deal & 2025 Outlook

Broadcom’s Financial Performance and Stock Trajectory Broadcom’s stock has been on a meteoric rise in 2023–2025, riding the twin waves of AI chip euphoria and strategic acquisitions. Even after the recent market volatility, AVGO is up dramatically year-to-date and over the past 12 months. At the start of 2024, Broadcom’s market cap was around $300 B; by October 2025 it ballooned past $1.5 trillion ts2.tech. The company’s decision to enact a 10:1 stock split (in February 2024) helped spur retail interest, while its fundamental performance justified the climb. Earnings momentum has been strong. In fiscal 2024 (ended Oct 2024), Broadcom’s revenue was
11 October 2025
····
TSMC’s AI-Fueled Surge: Record Highs, Big Risks, and Bold Predictions (Oct 2025 Update)

TSMC’s AI-Fueled Surge: Record Highs, Big Risks, and Bold Predictions (Oct 2025 Update)

TSMC Stock Soars on AI Boom TSMC (Taiwan Semiconductor Manufacturing Co.) is riding a wave of investor enthusiasm as of October 2025. Its Taipei-listed shares hit record highs this month – reaching NT$1,370 on Oct 2 (about $43 USD per share) ts2.tech – and the U.S. ADR (NYSE: TSM) likewise surged to all-time highs, briefly trading above $300. In fact, TSMC’s U.S. stock spiked to an intraday $307 on Oct 7 amid frenzied buying ts2.tech. Even after a bit of profit-taking, TSMC hovers around the mid-$290s per share as of Oct 11, reflecting a dramatic upswing from roughly ~$200 at
11 October 2025
····
Trump Media’s Wild Ride: DJT Stock Soars on Politics, Crypto & Controversy

Trump Media’s Wild Ride: DJT Stock Soars on Politics, Crypto & Controversy

Stock Price and Recent Performance As of mid-October 2025, DJT stock hovers around $15–$16, a far cry from its highs. It closed at $15.97 on October 10, 2025 investing.com investing.com, continuing a downward trend. The stock has lost roughly half its value in 2025 alone, and over the past year it’s down about 32% tickernerd.com. For context, DJT’s 52-week range spans from $15.42 up to $54.68 investing.com tickernerd.com – meaning it has collapsed about 70% from its peak. That peak came amid tremendous enthusiasm earlier in Trump’s presidential term, but momentum has since faded. Wild volatility is a hallmark of
11 October 2025
··
Robinhood’s Wild 2025 Ride: HOOD Stock Skyrockets 200%, Plunges 9% in a Day – What’s Next?

Robinhood’s Wild 2025 Ride: HOOD Stock Skyrockets 200%, Plunges 9% in a Day – What’s Next?

HOOD Stock Price and Recent Performance Robinhood’s stock has been on a rollercoaster in 2025. After starting the year at much lower levels, HOOD nearly tripled in value by early October. On October 6, shares hit a record intra-week high around $153. But by the week’s end, the stock pulled back sharply, closing at $138.96 on Oct 10 after an 8.9% single-day plunge ts2.tech. (The Oct 10 drop coincided with a broader market selloff sparked by renewed U.S.–China trade war fears, which particularly hit high-growth tech stocks ts2.tech.) Even after the pullback, Robinhood remains up over 200% year-to-date, vastly outperforming
11 October 2025
Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

(Source: Nasdaq/GlobeNewswire, Reuters, TipRanks, Finviz, company filings.) Company Overview: Rare Disease Focus and Pipeline Progress Quoin Pharmaceuticals Ltd. is a clinical-stage biotech specializing in rare dermatological diseases. Headquartered in Ashburn, VA, Quoin’s mission is to deliver the first approved therapies for conditions that currently have none. “We remain fully focused on delivering the first approved therapy for Netherton Syndrome,” said CEO Dr. Michael Myers globenewswire.com. The company’s pipeline comprises three main product candidates targeting multiple orphan indications finviz.com: Until recently, Quoin had additional assets (QRX004 for epidermolysis bullosa, and QRX007 for Netherton) but shelved those programs in mid-2025 to concentrate
11 October 2025
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseasesprotagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers on “developing groundbreaking new medicines to treat both rare and prevalent diseases” using its proprietary peptide platformprotagonist-inc.com. This focus has led to a pipeline addressing blood cancers/disorders and inflammatory bowel and skin diseases, where current treatments are inadequate. Leadership & Culture: President
11 October 2025
·····
1 … 1,469 1,470 1,471 1,472 1,473 … 1,639

Stock Market Today

Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

8 February 2026
Tower Semiconductor shares rose 7.7% to $139.04 Friday after announcing a collaboration with Nvidia on AI data-center networking. The stock touched $141 intraday and gained another 1% after hours. Investors await Tower’s Feb. 11 earnings for details on its silicon photonics work. No financial terms or shipment timeline were disclosed.
Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

8 February 2026
Longsys disclosed new guarantees for a 100 million yuan Hong Kong loan and a $9 million Brazil credit line, bringing its total approved guarantee quota to 11 billion yuan and outstanding guarantees to 5.81 billion yuan. The company said all guarantees are for consolidated subsidiaries and within approved limits. Shares closed at 288 yuan Friday, down 1.6%. China inflation and credit data are due this week.
MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

8 February 2026
MACOM shares rose 3.5% to $235.87 Friday after the company reported fiscal Q1 revenue of $271.6 million and raised its full-year data center growth outlook to 35–40%. Fidelity’s FMR LLC disclosed a 10.7% stake, while shareholder Susan Ocampo filed to potentially sell up to 100,000 shares. Stifel raised its price target to $255. MACOM expects to repay $161 million in convertible notes in March.
Go toTop